pharmaceutical career
pharmaceutical career with http://www.takeyourmeds.info

pharmaceutical career

Take Your Meds

News for 03-Sep-22

Source: MedicineNet Kids Health General
Health Tip: If Your Child is Cyberbullied

Source: MedicineNet Kids Health General
Growth Charts

Source: MedicineNet Kids Health General
Child Deaths Highlight Choking Dangers Posed by Grapes

Source: MedicineNet Kids Health General
Rest May Not Be Best for Kids After Concussion

Source: MedicineNet Kids Health General
Down Syndrome May Not Be Big Financial Burden on Families

Source: MedicineNet Kids Health General
Used Safely, Donor Breast Milk Can Help Preemie Babies

Source: MedicineNet Kids Health General
Teen Violence Can Be Contagious, Study Contends

Source: MedicineNet Kids Health General
Baby Crib Ads Show Unsafe Practices, Study Says

Source: MedicineNet Kids Health General
Some Kids' Genes Might Make Food Ads More Tempting

Source: MedicineNet Kids Health General
Teens May Not Heed Health Warnings on Cigars

Search the Web
pharmaceutical career
prescriptions from canada
drug policy
glaxowellcome
international pharmacies
prevacid
natures rx
freshers
revenues
pharmecuetical sales

The Best pharmaceutical career website

All the pharmaceutical career information you need to know about is right here. Presented and researched by http://www.takeyourmeds.info. We've searched the information super highway far and wide to provide you with the best pharmaceutical career site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
pharmaceutical career.

pharmaceutical career
pharmaceutical career, , pharmaceutical career, , pharmaceutical career,
http://www.medmeet.com/
CLICK HERE RIGHT NOW

pharmaceutical career

Take Your Meds
Most people skip taking their medication at certain times, this is bad for your health. Look to Take Your Meds on time and
Take Your Meds

If you've spent any time on the Internet looking for pharmaceutical career, you've seen those sites that use hype to sell their products. You can't miss hype, with its exclamation points, bold and caps text, and enthusiasm through the roof. But when is hype appropriate and will it really help you with your search for pharmaceutical career ?

If you visit a lot of pharmaceutical career sites on the net, you'll begin to notice that most of them are exactly the same. Sure, they are selling different brands of pharmaceutical career, but on the surface they are about as different as the Olsen twins.

"Orphan Drugs": Hope Where There Is Little or No Hope

 by: Alex Michelini

NEW YORK, N.Y., February 18, 2004 On a visit to his doctor, Gary Jacob received distressing news not about himself, but a friend of the doctor's.

While playing with one of his children, the doctor's friend fell and broke a rib. That was bad enough, but during the examination at the hospital, the father was hit with a startling and totally unexpected diagnosis he had a disease known as multiple myeloma, a bone marrow blood cancer.

The diagnosis was nothing less than a death sentence.

Jacob knew of the anguish of multiple myeloma patients. The disease is incurable and nearly always fatal, one of the rare diseases that have few, if any, available treatments. They are known as "orphan" diseases, shunned by most drug-makers because the patient populations are small and commercial development of a drug is seen as economically unattractive.

Mr. Jacob was aware because, as Chief Executive Officer of Callisto Pharmaceuticals, Inc., a small Manhattan-based biopharmaceutical company, he is leading a scientific effort to develop a new orphan drug called "Atiprimod" for multiple myeloma patients.

"The father's disease brought home to me that what we are doing is really important," says Mr. Jacob. "Everyone agrees we need more drugs to treat multiple myeloma. There are people out there dying without real hope because of a lack of effective treatment for all patients."

In steadily increasing numbers, orphan drugs are providing new doses of hope where little or none at all existed. In the decade before the inception of the federal Food and Drug Administration's orphan drug program, 10 drugs were developed by pharmaceutical companies for orphan diseases. In the decades since, the FDA says nearly 250 new drugs were developed and approved, and hundreds more are in the pipeline.

Atiprimod is one of those wending its way toward the marketplace. Callisto recently obtained orphan drug designation from the FDA, providing the company with financial incentives to continue the costly development process.

The program covers drugs for orphan diseases with patient populations under 200,000.

The National Organization for Rare Disorders reports about 25 million people in the United States suffer from an estimated 6,000 orphan diseases.

Diseases such as cystic fibrosis, complications affecting HIV-infected people, Gaucher's disease, hemophilia and rare forms of cancer were among the orphans without effective medicines until the FDA program went into effect in 1983 and paved the way for new drugs for patients with these diseases.

Large drug-makers have been largely missing from the efforts.

According to the orphan drug program's deputy director, Dr. John McCormick, only 15% of applications for orphan drug designation have come from the larger pharmaceutical companies.

The reason: expectations of unfavorable investment returns.

The FDA orphan drug incentives grants, seven years of marketing exclusivity and tax breaks have drawn small pharmaceutical companies with promising drug candidates into the breach.

While the future is brighter, the task is still daunting to develop drugs for orphan diseases.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, affects 30,000 Americans with 8,000 new cases diagnosed annually; Huntington's disease also affects about 30,000 patients.

Some diseases affect fewer than 100 patients, according to the National Institutes of Health.

An estimated 50,000 patients have multiple myeloma with 15,000 new patients diagnosed each year. Last year, the FDA approved a new drug Velcade for patients with the disease. However, there are still a number of multiple myeloma patients with no treatment available.

Dr. Kenneth C. Anderson, who played a major role in the preclinical development and clinical trials of Velcade and is now a member of Callisto's Medical Advisory Board, is among the experts who see a need for more drugs to treat multiple myeloma.

"He is excited to see Atiprimod enter clinical trials for evaluation in multiple myeloma patients," Jacob said of Anderson. "He believes it has an opportunity to help patients who have not responded to other drugs. "

Dr. Anderson is director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute in Boston, MA, and Professor of Medicine at Harvard Medical School.

The Phase I/IIa trials for Atiprimod are slated to begin later this month.

Dr. Donald Picker, Callisto's Senior Vice President of Drug Development, said studies of Atiprimod in collaboration with scientists at the National Cancer Institute have been very promising.

"In essence, we've shown in these early studies that Atiprimod has the potential to intervene with cancer cells and tumors in three ways by inhibiting their formation, by programming their death and by limiting their ability to grow blood vessels necessary for their survival. Taken together, these findings suggest that Atiprimod could potentially represent a novel class of compounds for development for therapeutic intervention in human cancers," said Dr. Picker.

##

About The Author

Alex Michelini is a former award-winning reporter/editor at the New York Daily News. His credits include nomination for a Pulitzer Prize for a series on medical costs. Among his honors, Mr. Michelini received the Deadline Club Award, the Page One Award, the Associated Press Award and the New York Press Club Award (twice). He is the founder of Alex Michelini Public Relations, and has developed and collaborated on articles appearing in the New York Times, the Wall Street Journal, the London Times, the New York Post, the New York Daily News, Bloomberg Radio & TV, CNNfn, WCBS Radio & TV. WINS radio, the Christian Science Monitor, Fox TV, Reuters, Newsday and other media outlets.


michelinialex@aol.com

Google

http://www.medmeet.com/
MD News | Talk On The Net | Real Time Media On The Net | Medical Presentations | Take It Right

Law Meet   Talk On The Net   Medical Meetings